RECURRENT HODGKIN LYMPHOMA
Clinical trials for RECURRENT HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2 or SWI/SNF) in their tumors. The goal was to see if the drug could shrink or control the cancer. This is a dise…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug flotetuzumab tested for tough blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of flotetuzumab, a lab-made antibody, in 13 people with advanced blood cancers that had come back or stopped responding to treatment. The goal was to see if the drug could help control the disease by blocking cancer cell grow…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Promising combo for Tough-to-Treat hodgkin lymphoma shows progress
Disease control CompletedThis study tested a new combination of a targeted drug (brentuximab vedotin) with standard chemotherapy for people whose Hodgkin lymphoma returned or didn't respond to treatment. The goal was to find the safest dose and see how many patients achieved complete remission. 45 adults…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC